The Cardiovascular Risk Factors, Aging, and Dementia Study

https://www.neurodegenerationresearch.eu/survey/the-cardiovascular-risk-factors-aging-and-dementia-study/

Title of the cohort

The Cardiovascular Risk Factors, Aging, and Dementia Study

Acronym for cohort

CAIDE

Name of Principal Investigator

Title	MD, PhD, Associate Professor
First name	Miia
Last name	Kivipelto

Address of institution where award is held

Institution	Aging Research Center, Karolinska Institutet
Street Address	
City	Stockholm
Postcode	113 30

Country

- Sweden

Website

http://www.uef.fi/caide/home

Contact email

Funding source

1) Swedish Research Council (VR)
2) Academy of Finland
3) Alzheimer Association
4) Novo-Nordisk

1. The cohort includes, or expects to include, incidence of the following conditions

- Alzheimer’s disease and other dementias
- Neurodegenerative disease in general

When studies on the above condition(s) are expected to become possible

- Already possible

2a. Stated aim of the cohort

To investiagte cardiovascular and lifestyle related risk factors for cognitive impairment and dementia

2b. Features distinguishing this cohort from other population cohorts

Data available already from midlife and follow-up time over 30 years

3a. i) Number of publications that involve use of cohort to date

50

3b. Publication list/link to where data or publications are accessible (if available)
3c. Information (i.e. research findings) expected to be gained from the population cohort
4a. Study criteria: age range of participants at recruitment

Age in years from: 65
To (‘until death’ if applicable): 79

4b. Study criteria: inclusion criteria

Differential diagnoses for dementing disorders including brain MRI, CSF, ECG, blood tests and more detailed neuropsyvhological evaluation

4c. Study criteria: exclusion criteria

No

5. Size of the cohort (i.e. number of participants enrolled)

- 1,000 – 5,000 participants

6a. Measures used to characterise participants

Cognitive tests, health and life-style questionnary, physcial examination, and blood samples

6b. Additional measures for participants with a clinical disorder

Mild cognitive impairment, dementia, Alzheimer’s disease

6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)

Cognitive impairment, mild cognitive impairment, dementia and Alzheimer’s disease

7. Study design

- Prospective cohort

8. Cases matched by

- Age

- Sex
- Other health assessment (specify) / N/A
- - We have used a reprentative population based sample. In some sub-studies, i.e. MRI we have used case-control design

9a. Does the study include a specialised subset of control participants

- No

9b. If yes, description of specialised subset of control participants
10a. i) Data collection start date

01-01-1998

10a. ii) Data collection end date
10a iii) Data collection for this study is

- Data analysis ongoing

10b. Plans to continue the cohort study beyond the current projected end date

- Yes – intend to apply for funding

11. Data collected

- Only through the study
- Through links to medical records

12. System in place to enable re-contact with patients for future studies

- Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)

13a. Format and availability of data stored in a database

	Yes/No	% available
Data summarised in database	yes	95
Database is web-based	no	
Database on spreadsheet	yes	
Database is on paper	yes	
Other (specify)		

Language used:

English

13b. Format and availability of data held as individual records
Language used:
14a. Are data available to other groups

Yes

14b. Access policy/mechanisms for access if data are available to other groups

- Access through collaboration with PI only

15. Data sharing policy specified as a condition of use

- No requirement to make data publicly available

16a. Are tissues/samples/DNA available to other groups

Yes

16b. i) Description of available tissues/samples/DNA

- Living donors:blood
- Living donors: DNA
- Living donors: cerebro-spinal fluid

16b. ii) Form available tissues/samples/DNA are supplied in
16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data

Yes

17. Is information on biological characteristics available to other groups

- Yes, for all the cohort